Moonpig flotation price, like so many, was always pie-in-the-sky thinking | Nils Pratley

You’d think fund mangers would have deployed degree of scepticism after years of overvalued businesses

Flotation fever is a dangerous condition, and the bout experienced in early 2021, we can now say, was severe. The cohort of stock market arrivals included (down 100% from its float price), Deliveroo (off 77%) and Dr Martens (47% lower). Now comes Moonpig. Floated at 350p, the online gifts and greetings cards retailer sits at 138p after Wednesday’s half-year update, which brought a revision to full-year in revenue forecasts from £350m to £320m

Moonpig seems reliably profitable – as Dr Martens is. One could even call the business model clever. The cards are printed only when the customer orders, which is terrific for cashflow, and the add-on gifts are a margin-enhancing opportunity to sell to a self-selecting audience.

It’s just that a £1.2bn price-tag at listing in February last year was plainly far too much. Yes, Moonpig can say it is “leveraging data and technology” with its ability to remind loyal punters that their great-aunt’s birthday is approaching, so best to get in quick before the next Royal Mail strike. But highly prized tech firms are not usually in the business of flogging chocolates, flowers and personalised mugs. The valuation ought to reflect as much.

Moonpig’s management has done nothing wrong, it should be said. Before Wednesday, they had upgraded on revenues a few times as a public company and, even now, expectations for operating profits haven’t changed much. There is also a fair argument that an ability to dial the marketing budget up or down, according to conditions, provides a degree of resilience. The beef is solely about the original over-the-top float price.

What were the fund managers smoking as the UK came out of lockdown? After buying too many businesses from private equity at inflated multiples over the years, you’d think they would have learned to deploy a little scepticism. Instead, they seem to have swallowed whole the notion that the Covid online whoosh would last for ever and thus traditional valuation yardsticks could be ignored. Some of these people, unfortunately, manage pensions.

Hard to swallow why markets panicked over Zantac

It’s too soon to say the great Zantac panic – the one that clobbered GlaxoSmithKline’s share price in the summer – is definitively over. Other US courts are scheduled to consider plaintiffs’ claims that a heartburn drug from the 1980s caused their cancer; and appeals can always happen. But the federal case in Florida, all sides agreed, was the big one. From the point of view of GSK and other pharma companies that had held the rights to Zantac over the decades, the verdict could not have been better.

As Redburn’s analysts put it: “There are victories … and then there is this.” Over 330 pages, Judge Robin Rosenberg dismissed thousands of claims in crystal-clear terms. Here’s a flavour: the plaintiffs scientists “utilised unreliable methodologies”, didn’t substantiate “analytical leaps”, had “a lack of internally consistent, objective, science-based standards for the even-handed evaluation of data”.

Naturally, GSK’s rose 13%, while Sanofi, the French pharma firm that acquired a company that sold Zantac, was up 7%. Haleon, the FTSE 100 consumer products firm that GSK demerged in July, rose 8% and is almost back at its original value.

It’s worth asking, then, why stock market investors worked themselves into such a frenzy over Zantac in the first place. The weirdness was that share prices almost seemed to imply that the pharma companies had already lost. GSK’s share fell 15% over two days in August when there was no other news around. Across the theoretically exposed companies, the decline in stock market value was about £30bn.

Why such a sudden drop? And, why did it happen even though the existence of the litigation was already known and had been explicitly detailed by GSK in its Haleon demerger prospectus? The short answer, strange as it sounds, is that a single note from a Morgan Stanley analyst seems to have triggered the scare by theorising about a “possible range” of $10.5bn to $45bn for total Zantac liabilities across the pharma industry.

Anything is “possible” in the US legal system, of course, but a $45bn payout for a drug that had been approved by regulators in many jurisdictions always felt like a very extreme scenario. After the Florida verdict, the litigation overhang now looks “eminently manageable”, in the view of Deutsche Bank’s analysts. File this episode as another instance of inefficient markets.


Nils Pratley

The GuardianTramp

Related Content

Article image fashion website soars on stock market – ending day at £840m
Shares in the fast-growing online retailer started trading on the junior Aim at 50p but within 10 minutes had jumped 70% to 85p

Zoe Wood

14, Mar, 2014 @6:21 PM

Article image
Royal Mail IPO could leave public purse royally short-changed
A 400p share price, which represents a 21% jump, would provoke fury among almost everyone – and rightly so

Nils Pratley

07, Oct, 2013 @6:13 PM

Article image
Aldermore abandons £800m flotation
Specialist bank cites deterioration of global equity markets as share prices tumble from recent peaks

Sean Farrell

15, Oct, 2014 @12:00 PM

Article image
Love Island is awful – but ITV's prospects are better | Nils Pratley
First-half ad revenues fell 8% as expected, but things are expected to improve – and the Netflix revolution has been overstated

Nils Pratley

27, Jul, 2017 @9:34 AM

Article image
London stock market review should help ordinary investors – not just tech
The government aims to encourage more technology companies to float, but wider reforms are needed

Nils Pratley

02, Mar, 2021 @7:08 AM

Article image
Alibaba on track to raise £10bn in Hong Kong listing
E-commerce group plans to sell 500m shares in biggest offering across global markets this year

Kalyeena Makortoff

20, Nov, 2019 @3:08 PM

Article image
M and M Direct considers stock market flotation
IPO would follow that of fellow online fashion business, which attracted a valuation of £560m

Sarah Butler

18, Mar, 2014 @9:27 PM

Article image
Anglo American defies 'value that lasts' motto in drift to foot of FTSE 100
Shares in mining company now cheaper than when it arrived on market in 1999 – while Tesco is another company down on its luck

Nils Pratley

08, Dec, 2015 @7:52 PM

Article image
The only party not getting heartburn over GSK demerger is the lawyers | Nils Pratley
The depressing outcome of the split is a legal challenge in the US over Zantac that will run on for years

Nils Pratley

20, Sep, 2022 @6:04 PM

Article image
City’s crisis of confidence in Matthew Moulding’s THG is real – and getting worse
Shares plunge 35% as THG sticks to ambition to demerge beauty and nutrition operations

Nils Pratley

12, Oct, 2021 @6:38 PM